These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8873669)

  • 21. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraplatelet tetrahydrobiopterin plays an important role in regulating canine coronary arterial thrombosis by modulating intraplatelet nitric oxide and superoxide generation.
    Kanaya S; Ikeda H; Haramaki N; Murohara T; Imaizumi T
    Circulation; 2001 Nov; 104(20):2478-84. PubMed ID: 11705828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries.
    Willerson JT; Igo SR; Yao SK; Ober JC; Macris MP; Ferguson JJ
    Tex Heart Inst J; 1996; 23(1):1-8. PubMed ID: 8680268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
    Yasuda T; Gold HK; Kohmura C; Guerrero L; Yaoita H; Fallon JT; Bunting S; Collen D
    Arterioscler Thromb; 1993 May; 13(5):738-47. PubMed ID: 8485125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.
    Przyklenk K; Frelinger AL; Linden MD; Whittaker P; Li Y; Barnard MR; Adams J; Morgan M; Al-Shamma H; Michelson AD
    J Thromb Haemost; 2010 Feb; 8(2):331-40. PubMed ID: 19922435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of adenosine on thrombosis and thrombolysis in a canine experimental preparation.
    Huang J; Feldbaum VM; Lucchesi BR; Werns SW
    Pharmacology; 2001; 63(3):166-74. PubMed ID: 11598423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhaled nitric oxide partially reverses hypoxic pulmonary vasoconstriction in the dog.
    Romand JA; Pinsky MR; Firestone L; Zar HA; Lancaster JR
    J Appl Physiol (1985); 1994 Mar; 76(3):1350-5. PubMed ID: 8005882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monophosphoryl lipid A: a novel nitric oxide-mediated therapy to attenuate platelet thrombosis?
    Przyklenk K; Hata K; Whittaker P; Elliott GT
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):366-75. PubMed ID: 10710120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation.
    Golino P; Ambrosio G; Ragni M; Pascucci I; Triggiani M; Oriente A; McNatt J; Buja LM; Condorelli M; Chiariello M
    Circulation; 1993 Sep; 88(3):1205-14. PubMed ID: 8353882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostacyclin aerosol and inhaled nitric oxide fail to reverse pulmonary vasoconstriction induced by thromboxane analogue in dogs.
    Welte M; Zwissler B; Habler O; Kleen M; Messmer K
    Acta Physiol Scand; 1995 Jul; 154(3):395-405. PubMed ID: 7572237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.
    Anderson HV; McNatt J; Clubb FJ; Herman M; Maffrand JP; DeClerck F; Ahn C; Buja LM; Willerson JT
    Circulation; 2001 Nov; 104(19):2331-7. PubMed ID: 11696474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.